National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

Statutory Rules

1975 No. 50

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1975.*

WHEREAS it is provided by sub-section 101 (4) of the National Health Act 1953-1975 that a drug or medicinal preparation that was not a pharmaceutical benefit under the National Health Act 1953-1958 immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of the National Health Act 1953-1975 unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

AND WHEREAS that Committee has recommended to the Minister that the following drugs and medicinal preparations be prescribed as pharmaceutical benefits under section 85 of the National Health Act 1953-1975, namely the drugs and medicinal preparations specified in the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations, as amended by the following Regulations, that had not previously been prescribed as pharmaceutical benefits:

NOW THEREFORE I, THE GOVERNOR-GENERAL of Australia, acting with the advice of the Executive Council, hereby make the following Regulations under the National Health Act 1953-1975.

Dated this twenty-seventh day of March 1975.

JOHN R. KERR

Governor-General.

By His Excellency’s Command,

D. EVERINGHAM

Minister of State for Health.

Amendments of the National Health (Pharmaceutical Benefits) Regulations 

Commencement.

1. These Regulations shall come into operation on 1 April 1975.

First Schedule.

2. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 1.

Second Schedule.

3. The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 2.

* Notified in the Australian Government Gazette on 1 April 1975.

  Statutory Rules 1960, No. 17, as amended by Statutory Rules 1960, Nos. 90 and 102; 1961, Nos. 59 and 137 1962, Nos. 34, 101 and 114; 1963, Nos. 34, 69 and 107; 1964, Nos. 12, 57 and 135; 1965, Nos. 51, 151 and 152 1966, Nos. 80 and 144; 1967, Nos. 67, 116 and 158; 1968, Nos. 44, 76, 88 and 146; 1969, Nos. 44, 107 and 185 1970, Nos. 39, 94, 119 and 186; 1971, Nos. 44, 101, 136 and 154; 1972. Nos. 32, 121 and 205; 1973, Nos. 15, 57, 139 and 229; and 1974, Nos. 37, 126 and 222.

Third Schedule.

4. The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 3.

Fourth Schedule.

5. The Fourth Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by omitting item 4.

Fifth Schedule.

6. The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 4.

SCHEDULE 1  Regulation 2

amendments of the first schedule to the national health (pharmaceutical

Benefits) Regulations

1. After item 26 insert the following items:—

“ 26a. Aspirin and Caffeine Tablets

26b. Aspirin and Codeine Tablets

26c. Aspirin and Codeine Tablets Soluble ”.

2. Omit item 108.

3. After item 139 insert the following item:—

“ 139a. Dienoestrol Tablets ”.

4. After item 155 insert the following item:—

“ 155a. Dimethisterone ”.

5. Omit item 159.

6. After item 176 insert the following item:—

“ 176a. Emetine Injection ”.

7. After item 210 insert the following item:—

“ 210a. Globin Zinc Insulin Injection ”.

8. After item 387 insert the following item:—

“ 387a. Phenobarbitone Sodium Tablets ”.

9. After item 412 insert the following items:—

“ 412a. Prednisolone Sodium Phosphate Injection

412b. Prednisone ”.

10. After item 459 insert the following item:—

“ 459a. Sodium Aminosalicylate ”.

11. After item 485 insert the following item:—

" 485a. Stilboestrol ”.

12. After item 539 insert the following item:—

“ 539a. Vasopressin Injection ”.

SCHEDULE 2  Regulation 3

Amendments of the Second Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. Omit item 68.

2. After item 70 insert the following item :—
“ 70a	Diphenoxylate Hydrochloride	Atropine Sulphate with Diphenoxylate Hydrochloride ”.
3. Omit item 80, substitute the following item:—
“ 80	Ethinyloestradiol ....................	Ethynodiol Diacetate with Ethinyloestradiol
Lynoestrenol with Ethinyloestradiol
Megestrol Acetate with Ethinyloestradiol
Norethisterone Acetate with Ethinyloestradiol
Norgestrel with Ethinyloestradiol ”.

Schedule 2—continued

4. After item 99 insert the following item:—
" 99a		Glucose Nutramigen ...............	— ”.
5. Omit item 137, substitute the following item:—
“ 137	Neomycin Sulphate ................		Hydrocortisone Acetate with Neomycin Sulphate
Hydrocortisone with Neomycin Sulphate
Colistin Sulphate with Neomycin Sulphate
Polymyxin B Sulphate with Bacitracin Zinc and Neomycin Sulphate
Polymyxin B Sulphate with Gramicidin and Neomycin Sulphate
Polymyxin B Sulphate with Hydrocortisone and Neomycin Sulphate
Bacitracin with Polymyxin B Sulphate and Neomycin Sulphate
Thonzonium Bromide with Thonzylamine Hydrochloride, Hydrocortisone Acetate, Gramicidin and Neomycin Sulphate
Gramicidin with Nystatin, Triamcinolone Acetonide and Neomycin Sulphate
Natamycin with Hydrocortisone and Neomycin Sulphate ”.

6. Omit item 149.

SCHEDULE 3  Regulation 4

Amendments of the Third Schedule to the National Health (Pharmaceutical

Benefits) Regulations

1. Omit item 27.

2. After item 49 insert the following item:—

“ 49a. Bleomycin Sulphate ”.

3. Omit item 103.

4. After item 145 insert the following item:—

“ 145a. Glucose Nutramigen ".

5. After item 178 insert the following item:—

“ 178a. Insulin Injection Neutral, Specially Purified—Monocomponent ”.

6. After item 181 insert the following items:—

“ 181a. Insulin Isophane Injection Special P (Pig)

181b. Insulin Zinc Suspension (Amorphous), Specially Purified Injection—Monocomponent ”.

7. Omit item 211.

8. After item 223 insert the following item:—

“ 223a. Mithramycin ”.

9. Omit item 227, substitute the following item:—

“ 227. Nandrolone Hexyloxyphenylpropionate ”.

10. Omit item 232.

11. Omit item 286.

12. After item 308 insert the following item:—

“ 308a. Sea Wasp Antivenene ”.

SCHEDULE 4  Regulation 6

Amendments of the Fifth Schedule to the National Health (Pharmaceutical

Benefits) Regulations

1. Omit item 2.

2. Omit item 13, substitute the following item:—
“13	Azathioprine ..........................			Any disease or condition in a patient receiving treatment in or at an approved hospital.
With the written authority of the Director-General— Anaemia, autoimmune haemolytic
Arthritis, rheumatoid with vasculitis or visceral complications.
Continuing azathioprine therapy after discharge from an approved hospital
Crohn’s disease
Dermatomyositis
Granulomatosis, Wegener’s
Hepatitis, active chronic
Lupus erythematosus, systemic
Nephritis
Nephrotic syndrome
Organ transplant
Pemphigus vulgaris
Polyarteritis nodosa
Pyoderma gangrenosum
Scleroderma
Thrombocytopenic purpura
Ulcerative colitis ”.
3. After item 20 insert the following item:—
“ 21	Bleomycin Sulphate ...............		Squamous cell carcinoma
Choriocarcinoma of the testis
Embryonal cell carcinoma of the testis
Lymphoma ”.
4. Omit item 29, substitute the following item:—
“ 29	Carbenoxolone Tablets, B.P.		Gastric ulcer where a radiological examination or other tests have confirmed the presence of a gastric ulcer ”.
5. Omit item 40, substitute the following item:—
“ 40	Cholestyramine .....................	With the written authority of the Director-General— Bile salt malabsorption associated with ileal resection or proven ileal disease
Pruritus associated with partial biliary obstruction not responding to other therapy
Treatment of hypercholesterolaemia ”.

6. Omit item 59.

7. Omit item 68.

8. Omit item 69, substitute the following item:—
“ 69	Ethyloestrenol ........................		With the written authority of the Director-General—
Osteoporosis
Patients on long-term treatment with corticosteroids ”.
9. Omit item 73, substitute the following item:—
“ 73	Fluoxymesterone Tablets B.P.	Carcinoma of the breast
Hypogonadism
With the written authority of the Director-General—
Aplastic anaemias, proven
Osteoporosis ”.

10. Omit item 78.

Schedule 4—continued

11. After item 83 insert the following item:—
“ 84	Glucose Nutramigen ...............				With the written authority of the Director-General—
Cow’s milk allergy in children who have not attained the age of 6 years
Cystic fibrosis (mucoviscidosis)
Galactosaemia
Lactose intolerance ”.
12. After item 98 insert the following items:—
“ 99	Insulin Injection Neutral, Specially Purified—Monocomponent		Insulin resistance due to antibodies or disabling local reactions
100	Insulin Zinc Suspension (Amorphous), Specially Purified Injection—Monocomponent		Insulin resistance due to antibodies or disabling local reactions ”.
13. Omit item 110, substitute the following item:—
“ 110	(1) Lincomycin Hydrochloride, B.P.	Osteomyelitis ”.
(2) Lincomycin Capsules, B.P.
14. After item 110 insert the following item:—
“ 111	Lincomycin Injection, B.P. ..		Gram-positive coccal infections where these cannot be safely and effectively treated with penicillin or a derivative of penicillin ”.
15. Omit item 118, substitute the following item:—
“ 118	Medroxyprogesterone Acetate Tablets, 10 mg			Malignant neoplasia
Precocious puberty
Turner’s syndrome ”.

16. Omit item 119b.

17. Omit item 120, substitute the following item:—
“ 120	Megestrol Acetate B.P. with Ethinyloestradiol, B.P.			Treatment, including fertility control, of females with acne, hirsutism or sexual infantilism ”.
18. Omit item 124, substitute the following item:—
“ 124	(1) Methandienone Tablets B.P.		With the written authority of the Director-General— Osteoporosis
(2) Methenolone Acetate		Patients on long-term treatment with corticosteroids ”.
19. After item 131, insert the following item:—
" 132	Mithramycin ..........................			For use in a hospital for—
Inoperable testicular neoplasm
Symptomatic hypercalcaemia and hypercalcinuria associated with advanced neoplasia ”.
20. Omit items 136, 137 and 138, substitute the following items:—
“ 136	Nandrolone Decanoate ...........	Carcinoma of the breast
With the written authority of the Director-General— Osteoporosis
Patients on long-term treatment with corticosteroids
137	Nandrolone Hexyloxyphenylpropionate	Carcinoma of the breast With the written authority of the Director-General— Osteoporosis
Patients on long-term treatment with corticosteroids
138	Nandrolone Phenylpropionate	Carcinoma of the breast
Injection B.P.	With the written authority of the Director-General—
Osteoporosis
Patients on long-term treatment with corticosteroids ”.

Schedule 4—continued

21. Omit items 146 and 147, substitute the following item:—
“ 146	Norethisterone Tablets, B.P. 5 mg	Endometriosis Metropathia haemorrhagica
Precocious puberty
Turner’s syndrome ”.

22. Omit item 159.

23. Omit item 170, substitute the following item:—
“ 170	(1) Practolol Injection, B.P.	With the written authority of the Director-General—
(2) Practolol Tablets, B.P.	For the treatment of patients frequently disabled by attacks of angina in whom no evidence of cardiac failure is found, being patients in respect of whom other beta-blocking drugs should not be used because the patient suffers from bronchial asthma or any other condition associated with bronchospasm
For the treatment of patients suffering from serious arrhythmias, being patients in respect of whom other beta-blocking drugs should not be used because the patient suffers from bronchial asthma or any other condition associated with bronchospasm ”.

24. Omit items 174 and 175.

25. Omit item 193, substitute the following item:—
“ 193	Stanolone ..............................	Carcinoma of the breast
With the written authority of the Director-General— Osteoporosis
Patients on long-term treatment with corticosteroids ”.

26. Omit item 219.